These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24071736)

  • 1. Application of bispecific antibody against antigen and hapten for immunodetection and immunopurification.
    Kim H; Park S; Lee HK; Chung J
    Exp Mol Med; 2013 Sep; 45(9):e43. PubMed ID: 24071736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.
    Yoon S; Kim YH; Kang SH; Kim SK; Lee HK; Kim H; Chung J; Kim IH
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):227-33. PubMed ID: 24292501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific anti-mPDGFRβ x cotinine scFv-C
    Kim S; Kim H; Jo DH; Kim JH; Kim SR; Kang D; Hwang D; Chung J
    Methods; 2019 Feb; 154():125-135. PubMed ID: 30292795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds.
    Kim H; Yoon S; Chung J
    BMB Rep; 2014 Mar; 47(3):130-4. PubMed ID: 24499668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease.
    Benschop RJ; Chow CK; Tian Y; Nelson J; Barmettler B; Atwell S; Clawson D; Chai Q; Jones B; Fitchett J; Torgerson S; Ji Y; Bina H; Hu N; Ghanem M; Manetta J; Wroblewski VJ; Lu J; Allan BW
    MAbs; 2019; 11(6):1175-1190. PubMed ID: 31181988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dimeric bispecific miniantibody combines two specificities with avidity.
    Müller KM; Arndt KM; Plückthun A
    FEBS Lett; 1998 Jul; 432(1-2):45-9. PubMed ID: 9710248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
    Zou J; Chen D; Zong Y; Ye S; Tang J; Meng H; An G; Zhang X; Yang L
    Cancer Sci; 2015 May; 106(5):512-21. PubMed ID: 25664501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
    Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM
    Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of bispecific single chain antibodies expressed in Escherichia coli.
    Kranz DM; Gruber M; Wilson ER
    J Hematother; 1995 Oct; 4(5):403-8. PubMed ID: 8581376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles.
    Thorey IS; Grote M; Mayer K; Brinkmann U
    Methods Mol Biol; 2016; 1364():219-34. PubMed ID: 26472454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and analysis of scFv-IgG bispecific antibody size variants.
    Cao M; Wang C; Chung WK; Motabar D; Wang J; Christian E; Lin S; Hunter A; Wang X; Liu D
    MAbs; 2018; 10(8):1236-1247. PubMed ID: 30130449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
    Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
    Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of antigen-binding properties of bispecific antibodies.
    Smirnova MB; Dergunova NN; Kizim EA; Massino YuS ; Nikulina VA; Segal OL; Tereshkina EB; Kolyaskina GI; Dmitriev AD
    Biochemistry (Mosc); 1997 Jan; 62(1):41-8. PubMed ID: 9113728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region.
    Alt M; Müller R; Kontermann RE
    FEBS Lett; 1999 Jul; 454(1-2):90-4. PubMed ID: 10413102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.
    Jin J; Park G; Park JB; Kim S; Kim H; Chung J
    Exp Mol Med; 2018 May; 50(5):1-14. PubMed ID: 29795377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.